Skip to content

The Indigo System in Acute Lower Limb Malperfusion

Indian Registry (The INDigo System in Acute Lower Limb malperfusioN)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03386370
Acronym
INDIAN
Enrollment
150
Registered
2017-12-29
Start date
2017-09-01
Completion date
2019-05-31
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemia of Lower Limb

Keywords

Acute ischemia, Lower Limb

Brief summary

To evaluate, in a controlled setting, the early safety and effectiveness of the Penumbra/Indigo aspiration thrombectomy Systems (San Francisco, California), and to define optimal technique for the use of these systems in patients with confirmed peripheral acute occlusions.

Interventions

DEVICEIndigo Mechanical Thrombectomy System

Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra

Sponsors

Azienda Ospedaliera Universitaria Senese
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients will be selected based on the investigator's assessment and evaluation of the underlying disease. The patient's medical condition should be stable, with no underlying medical condition that would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for mid term follow-up. Patients who do not wish to participate in this study can obtain any other standard commercially available device therapy. Refusal to participate in this study will in no way affect their care at the institution. Inclusion Criteria * Patient presenting with an acute occlusion of lower limb arteries (thrombosis no longer than 14 days) * Patient presenting a score from I to IIb following Rutherford classification for acute limb ischemia * Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study * Patient is \>18 years old * Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * Patient is eligible for treatment with the Indigo System (Penumbra)

Exclusion criteria

* Estimated time of intraluminal thrombus \> 14 days * Patients refusing treatment * Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated * Patients with a history of prior life-threatening contrast medium reaction * Life expectancy of less than six months * Any patient considered to be hemodynamically unstable at onset of procedure

Design outcomes

Primary

MeasureTime frameDescription
Technical success of the thromboaspiration with the Indigo system.At intra-procedural completion angiographyThe primary endpoint of the study is the technical success of the thromboaspiration with the Indigo system. Assessment of vessel patency will be recorded using the Thrombolysis in Myocardial Infarction (TIMI) score classifications both before and after use of the device.

Secondary

MeasureTime frameDescription
Clinical success at 1 month follow-up.1 monthClinical success at follow-up is defined as an improvement of Rutherford classification at 1-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.
Safety Rate at discharge: Serious adverse event.1 monthSafety rate at discharge, defined as absence of any serious adverse events (SAE). A SAE is defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability.
Primary Patency1 monthPrimary patency at 1 month. Primary patency is defined as a target lesion without a hemodynamically significant stenosis/reocclusion on duplex ultrasound (\>50%,) and without target lesion reintervention (TLR) within 1 month.

Countries

Italy

Contacts

Primary ContactGianmarco de Donato, MD
dedonato@unisi.it+390577585123
Backup ContactCarlo Setacci, MD
setacci@unisi.it+390577233443

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026